Najarian D - Search Results

1

Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma.

Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, Halpern A, Rebbeck TR. Kanetsky PA, et al. Among authors: najarian d. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):509-13. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11352862

2

Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach.

Kanetsky PA, Ge F, Najarian D, Swoyer J, Panossian S, Schuchter L, Holmes R, Guerry D, Rebbeck TR. Kanetsky PA, et al. Among authors: najarian d. Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):808-19. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15159314

3

Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays.

Walker AH, Najarian D, White DL, Jaffe JF, Kanetsky PA, Rebbeck TR. Walker AH, et al. Among authors: najarian d. Environ Health Perspect. 1999 Jul;107(7):517-20. doi: 10.1289/ehp.99107517. Environ Health Perspect. 1999. PMID: 10378997 Free PMC article.

4

Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis.

Lopena OJ, Alphs LD, Sajatovic M, Turkoz I, Sun L, Johnston KL, Sliwa JK, Najarian DM, Starr HL. Lopena OJ, et al. Among authors: najarian dm. J Clin Psychiatry. 2023 Sep 25;84(6):23m14788. doi: 10.4088/JCP.23m14788. J Clin Psychiatry. 2023. PMID: 37756123 Free article.

5

Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia.

Najarian D, Turkoz I, Knight RK, Galderisi S, Lamaison HF, Zalitacz P, Aravind S, Richarz U. Najarian D, et al. Int J Neuropsychopharmacol. 2023 Aug 29;26(8):537-544. doi: 10.1093/ijnp/pyad028. Int J Neuropsychopharmacol. 2023. PMID: 37480362 Free PMC article. Clinical Trial.

6

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia.

Milz R, Benson C, Knight K, Antunes J, Najarian D, Lopez Rengel PM, Wang S, Richarz U, Gopal S, Kane JM. Milz R, et al. Among authors: najarian d. Neuropsychiatr Dis Treat. 2023 Mar 7;19:531-545. doi: 10.2147/NDT.S395383. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 36915909 Free PMC article. Review.

7

Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections.

Turkoz I, Daskiran M, Starr HL, Najarian D, Lopena O, Obando C, Keenan A, Benson C, Gopal S. Turkoz I, et al. Among authors: najarian d. Neuropsychiatr Dis Treat. 2022 Aug 30;18:1927-1937. doi: 10.2147/NDT.S373725. eCollection 2022. Neuropsychiatr Dis Treat. 2022. PMID: 36065384 Free PMC article.

8

Baseline risk characterization of early versus later adopters of long-acting paliperidone palmitate formulations.

Fife D, Fortin S, Qiu H, Yamazaki M, Najarian D, Voss EA. Fife D, et al. Among authors: najarian d. Neuropsychopharmacol Rep. 2022 Sep;42(3):347-351. doi: 10.1002/npr2.12260. Epub 2022 Jun 1. Neuropsychopharmacol Rep. 2022. PMID: 35650169 Free PMC article.

9

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.

Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. Najarian D, et al. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071. Int J Neuropsychopharmacol. 2022. PMID: 34791283 Free PMC article. Clinical Trial.

10

Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine-Conjugated RNA Interference Therapeutic.

Li J, Liu J, Zhang X, Clausen V, Tran C, Arciprete M, Wang Q, Rocca C, Guan LH, Zhang G, Najarian D, Xu Y, Smith P, Wu JT, Chong S. Li J, et al. Among authors: najarian d. Drug Metab Dispos. 2021 Jul;49(7):572-580. doi: 10.1124/dmd.121.000381. Epub 2021 May 3. Drug Metab Dispos. 2021. PMID: 33941543

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters